SEC Form 4 · accession 0001209191-17-030982
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Engelhart
Officer — Chief Financial Officer
Period of report
May 9, 2017
Accepted (ET)
May 9, 2017 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | May 9, 2017 | C | 1,076 | — | A | 1,076 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred SharesF2 | — | May 9, 2017 | C | 1,076 | D | — | — | Common Shares | 1,076 | 0 | D |
Explanation of responses
- F1Represents shares received upon conversion of Series A Preferred Shares.
- F2Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date.